Literature DB >> 12617267

Conversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fluid and neurophysiological findings.

J Sastre-Garriga1, M Tintoré, A Rovira, E Grivé, I Pericot, M Comabella, A J Thompson, X Montalban.   

Abstract

BACKGROUND AND AIM: Conversion to multiple sclerosis (MS) after optic neuritis and myelitis has been thoroughly studied; however, limited data are available regarding conversion to MS after a clinically isolated syndrome of the brainstem (CISB). The aim of this study was to investigate conversion to MS in patients with CISB.
METHODS: Fifty-one patients with CISB were prospectively studied. Cranial magnetic resonance imaging (MRI), determination of oligoclonal bands (OBs) in the cerebrospinal fluid (CSF) and evoked potentials (EPs) were performed. Based on conversion to MS at follow-up, the sensitivity, specificity, accuracy and positive and negative predictive values of these tests were calculated.
RESULTS: Clinically definite MS developed in 18 (35%) patients after a mean follow-up of 37 months. Paty's MRI criteria showed a sensitivity of 89%, a specificity of 52% and an accuracy of 65%; Fazekas' criteria showed a sensitivity of 89%, a specificity of 48% and an accuracy of 63%; Barkhof's criteria showed a sensitivity of 78%, a specificity of 61% and an accuracy of 67%. The presence of OBs in the CSF showed a sensitivity of 100%, a specificity of 42% and an accuracy of 63%. No differences for neurophysiological parameters were found between patients who did and those who did not convert to MS.
CONCLUSION: Fulfilling Paty's, Fazekas' or Barkhof's MRI criteria and the presence of OBs in the CSF are associated with a higher risk of conversion to MS in patients with CISB. Determination of OBs in the CSF has the greatest sensitivity of all tests. Barkhof's MRI criteria have greater specificity (although less than previously published for mixed cohorts of clinically isolated syndromes) in predicting conversion to MS for CISB than either Paty's or Fazekas' criteria.

Entities:  

Mesh:

Year:  2003        PMID: 12617267     DOI: 10.1191/1352458503ms847oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  9 in total

1.  Clinical features of CIS of the brainstem/cerebellum of the kind seen in MS.

Authors:  Jaume Sastre-Garriga; M Tintoré; C Nos; C Tur; J Río; N Téllez; J Castilló; A Horga; H Perkal; M Comabella; A Rovira; X Montalban
Journal:  J Neurol       Date:  2009-11-28       Impact factor: 4.849

Review 2.  [Radiologically isolated syndrome: multiple sclerosis based solely on MRI findings?].

Authors:  J Sellner; L Schirmer; B Hemmer; M Mühlau
Journal:  Nervenarzt       Date:  2010-10       Impact factor: 1.214

3.  Risk of multiple sclerosis following clinically isolated syndrome: a 4-year prospective study.

Authors:  Roberto D'Alessandro; Luca Vignatelli; Alessandra Lugaresi; Elisa Baldin; Franco Granella; Maria Rosaria Tola; Susanna Malagù; Luisa Motti; Walter Neri; Massimo Galeotti; Mario Santangelo; Laila Fiorani; Enrico Montanari; Cinzia Scandellari; Maria Donata Benedetti; Maurizio Leone
Journal:  J Neurol       Date:  2013-02-03       Impact factor: 4.849

4.  Updates on clinically isolated syndrome and diagnostic criteria for multiple sclerosis.

Authors:  Jacqueline F Marcus; Emmanuelle L Waubant
Journal:  Neurohospitalist       Date:  2013-04

Review 5.  Idiopathic inflammatory-demyelinating diseases of the central nervous system.

Authors:  A Rovira Cañellas; A Rovira Gols; J Río Izquierdo; M Tintoré Subirana; X Montalban Gairin
Journal:  Neuroradiology       Date:  2007-02-28       Impact factor: 2.995

6.  Gastroparesis secondary to a demyelinating disease: a case series.

Authors:  Savio C Reddymasu; John Bonino; Richard W McCallum
Journal:  BMC Gastroenterol       Date:  2007-01-31       Impact factor: 3.067

7.  Multiple sclerosis presented as clinically isolated syndrome: the need for early diagnosis and treatment.

Authors:  Sigliti-Henrietta Pelidou; Sotirios Giannopoulos; Sotiria Tzavidi; Georgios Lagos; Athanassios P Kyritsis
Journal:  Ther Clin Risk Manag       Date:  2008-06       Impact factor: 2.423

8.  Response to Therapeutic Plasma Exchange as a Rescue Treatment in Clinically Isolated Syndromes and Acute Worsening of Multiple Sclerosis: A Retrospective Analysis of 90 Patients.

Authors:  Johannes Ehler; Sebastian Koball; Martin Sauer; Steffen Mitzner; Heiko Hickstein; Reiner Benecke; Uwe K Zettl
Journal:  PLoS One       Date:  2015-08-05       Impact factor: 3.240

9.  Proteomic analysis of cerebrospinal fluid for relapsing-remitting multiple sclerosis and clinically isolated syndrome.

Authors:  Zbyšek Pavelek; Oldřich Vyšata; Vojtěch Tambor; Kristýna Pimková; Dai Long Vu; Kamil Kuča; Pavel Šťourač; Martin Vališ
Journal:  Biomed Rep       Date:  2016-04-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.